1. Home
  2. SRRK vs SHOO Comparison

SRRK vs SHOO Comparison

Compare SRRK & SHOO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRRK
  • SHOO
  • Stock Information
  • Founded
  • SRRK 2012
  • SHOO 1990
  • Country
  • SRRK United States
  • SHOO United States
  • Employees
  • SRRK N/A
  • SHOO N/A
  • Industry
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • SHOO Shoe Manufacturing
  • Sector
  • SRRK Health Care
  • SHOO Consumer Discretionary
  • Exchange
  • SRRK Nasdaq
  • SHOO Nasdaq
  • Market Cap
  • SRRK 2.8B
  • SHOO 3.1B
  • IPO Year
  • SRRK 2018
  • SHOO 1993
  • Fundamental
  • Price
  • SRRK $26.49
  • SHOO $43.23
  • Analyst Decision
  • SRRK Strong Buy
  • SHOO Hold
  • Analyst Count
  • SRRK 7
  • SHOO 8
  • Target Price
  • SRRK $34.00
  • SHOO $45.38
  • AVG Volume (30 Days)
  • SRRK 984.5K
  • SHOO 816.2K
  • Earning Date
  • SRRK 11-12-2024
  • SHOO 11-07-2024
  • Dividend Yield
  • SRRK N/A
  • SHOO 1.94%
  • EPS Growth
  • SRRK N/A
  • SHOO 6.16
  • EPS
  • SRRK N/A
  • SHOO 2.36
  • Revenue
  • SRRK N/A
  • SHOO $2,220,323,000.00
  • Revenue This Year
  • SRRK N/A
  • SHOO $15.16
  • Revenue Next Year
  • SRRK N/A
  • SHOO $5.30
  • P/E Ratio
  • SRRK N/A
  • SHOO $18.35
  • Revenue Growth
  • SRRK N/A
  • SHOO 14.89
  • 52 Week Low
  • SRRK $6.76
  • SHOO $36.23
  • 52 Week High
  • SRRK $35.38
  • SHOO $50.01
  • Technical
  • Relative Strength Index (RSI)
  • SRRK 50.87
  • SHOO 35.28
  • Support Level
  • SRRK $25.86
  • SHOO $43.18
  • Resistance Level
  • SRRK $28.11
  • SHOO $45.51
  • Average True Range (ATR)
  • SRRK 1.68
  • SHOO 1.38
  • MACD
  • SRRK -0.92
  • SHOO -0.14
  • Stochastic Oscillator
  • SRRK 11.71
  • SHOO 2.59

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

About SHOO Steven Madden Ltd.

Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its own stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.

Share on Social Networks: